NephroGenex Inc fka NRXGQ

[TheFinalCD]

on a stick...


the correct phrase is on a stick

[OB_WEALTH_INC]

Good job...it helps to look at historic chart before making decision and NRX chart is SH&^%T in a stick.

[TheFinalCD]

NOT (1) SINGLE SHARE

SORRY TO DISAPPOINT YOU



[9:42:51 AM] [SMART MONEY] .: NRX FALLIN NOW
[9:42:58 AM] [SMART MONEY] .: GLAD WE DIDNT CHASE
[9:43:11 AM] [SMART MONEY] .: 2.27 TO 1.41
[9:43:14 AM] [SMART MONEY] .: SOBZ

[OB_WEALTH_INC]

Oh smart money...yes you did...come on...really...

[TheFinalCD]

i didnt buy any silly goose

I just commented on the G&T

if I am always in the wrong place why do you follow me?

[OB_WEALTH_INC]

LOL SM YOU ALL IN THE WRONG PLACES LATELY WEEEEEEEEEEEE

look at its history..no known former runs...lots of downtrend ..history my friend..look at history first..

[TheFinalCD]

HORRIBLE GAP & TRAP!!!!!!!


NRX

[slickinvest]

It was a wild ride today!!

[shiftieone]

Have you seen the names and credentials signing on to their board? Will take a while but this will be big with opportunities to trade in and out on the way.

[declaes]

And when will this fly?

[ClayTrader]

* * $NRX Video Chart 12-14-15 * *

Link to Video - click here to watch the technical chart video

[shiftieone]

This will FLY. I'm in the medical field and this is a big issue without other treatments.....

[UP Trend]

Wow good news. Surprised this is not much higher with such a tiny OS, watching.

[stocktrademan]

$NRX recent news/filings

bearish 2.11

## source: finance.yahoo.com

Fri, 13 Nov 2015 12:14:37 GMT ~ NEPHROGENEX, INC. Files SEC form 8-K, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/151113/nrx8-k.html
*********************************************************

Thu, 12 Nov 2015 11:15:44 GMT ~ NEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/151112/nrx8-k.html
*********************************************************

Wed, 11 Nov 2015 21:16:13 GMT ~ NephroGenex Reports Third Quarter 2015 Financial Results

[at noodls] - RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business ...

read full: http://www.noodls.com/view/1C1116C2BACD9E761AA64F3C32E5F7885BA5B5CE
*********************************************************

Wed, 11 Nov 2015 21:05:00 GMT ~ NephroGenex Reports Third Quarter 2015 Financial Results

[Business Wire] - NephroGenex, Inc. , a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2015.

read full: http://finance.yahoo.com/news/nephrogenex-reports-third-quarter-2015-210500626.html
*********************************************************

Wed, 11 Nov 2015 12:07:03 GMT ~ Q3 2015 NephroGenex Inc Earnings Release - After Market Close


read full: http://biz.yahoo.com/research/earncal/20151111.html?t=nrx
*********************************************************

$NRX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NRX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NRX/company-info
Ticker: $NRX
OTC Market Place: Not Available
CIK code: not found
Company name: NephroGenex, Inc.
Incorporated In:

$NRX share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$NRX extra dd links

Company name: NephroGenex, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NRX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NRX/news - http://finance.yahoo.com/q/h?s=NRX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=NephroGenex%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=NephroGenex%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=NephroGenex%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NRX/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NRX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NRX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NRX



$NRX DD Notes ~ http://www.ddnotesmaker.com/NRX

[willlbone]

Dilution at $2.55 plus 20% punishment so price headed to $2.00.

[candeeman]

NRX Institutional ownership up 22.97% Quarter/Quarter

http://finance.yahoo.com/q/it?s=NRX+Insider+Transactions

[MrPoppaGeorgeo]

NRX beats by .04

[candeeman]

NephroGenex Coverage Initiated by Analysts at MLV & Co at buy PT $20

http://www.mideasttime.com/nephrogenex-coverage-initiated-by-analysts-at-mlv-co-nrx/380676/

[jlax]

Any thoughts on that 8k they filed Thursday?

[candeeman]

Nephrogenex to Present at the Noble Financial Capital Markets Equity Conference on January 20th at 10:30am EST

http://www.businesswire.com/news/home/20150114005111/en/Nephrogenex-Present-Noble-Financial-Capital-Markets-Equity

[Ice86]

Phase 3 DONE!!! THE Europe EMA said:)All in and hold my shares

[rand0m]

Welcome to biotech. Clinical stage company relies on news like this to build confidence that their product might have a shot at the market.

[MONEYMADE]

$11's (honestly not sure how this news is moving NRX)

[Ice86]

It means Pyridorin® can be released on the Europe market before US?

[rand0m]

I had been loading... sold a portion after hour though

[TheFinalCD]

[MONEYMADE]

WELL ONE OF THEM SHOULD BE FIRED! HAHAHAA WTF!!! BOOOOOOOM

[MONEYMADE]

MAJOR NEWS AH: NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic ...
Date : 01/07/2015 @ 5:00PM

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin® in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment. The EMA indicated that the current Phase 3 program could be adequate to support a Marketing Authorization Application for full market approval in Europe.

“The EMA’s support of our pivotal Phase 3 trial in Pyridorin strengthens our global regulatory strategy for this important clinical program,” said Chief Executive Officer Pierre Legault. “Diabetic nephropathy is a growing problem around the world, and Pyridorin has the potential to improve the care of the millions of patients who suffer from diabetic kidney disease and have few therapeutic options.”

Study Details

The Company’s PIONEER program includes two identical double-blind placebo controlled Phase 3 trials. Each is designed to evaluate the safety and efficacy of Pyridorin at 300 mg twice a day compared to placebo in reducing the rate of renal disease progression in Type 2 diabetic patients. Primary efficacy endpoints are time to a 50% increase in serum creatinine levels, or end stage renal disease. The first Phase 3 study was launched in June 2014.

Regulatory

Scientific advice or protocol assistance received from the EMA is not legally binding with regard to any future marketing authorization application of the product concerned, neither on the EMA nor on the sponsor of a clinical trial. Nevertheless, the advice provided is taken into consideration during MAA and any deviations from the advice given need to be well justified.

About Diabetic Nephropathy

Diabetic nephropathy is a chronic, degenerative disease of the kidney caused by diabetes. There are approximately 6 million patients with diabetic nephropathy in the United States (approximately 33% of diagnosed diabetics) and this population is expected to grow. Patients suffering from diabetic nephropathy progress to End Stage Renal Failure (and require dialysis) or death. There are currently no adequate treatments for this disease.

About Pyridorin®

Pyridorin inhibits pathogenic oxidative chemistries, which are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy. Pyridorin inhibits a broad range of these chemistries which we believe accounts for its effectiveness in slowing the progression of nephropathy in diabetic patients as shown in our Phase 2 studies. Our lead drug candidate was also found to be safe and well tolerated in these same studies.

About NephroGenex, Inc.

NephroGenex (Nasdaq: NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.

[TheFinalCD]

BOTH MOD$ MI$$ED THE NEW$


http://ih.advfn.com/p.php?pid=nmona&article=65022386

[candeeman]

NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic Nephropathy

[Ice86]

Time to load,building position today

[oxnous]

Without news, NRX is bound to retreat from such a great one day gain. Too tempting for flippers, imo, to take profits.

NRX will probably be at a number of biotech/pharmaceutical conferences in the next two months. That should increase the trading volume and buyers' interest.

[rand0m]

it will go back up 15++ im sure. just need to enter at a good price again. I'm buying at this level, slowly though

[rock5463]

This thing is done! I'd get out while you still can.

[MONEYMADE]

YEAAAA SUX BAAAAAAAAAAAAAAAAA%$#! BUT IT IS FRIDAY.

[TheFinalCD]

VOLUME IS ANEMIC IN COMPARISON , IMO FUNDS LOADED AND HOLDING FOR FUTURE EVENT$

[TheFinalCD]

I MISSED $10'S FOR THE BOUNCE= GRRRRRR

[MONEYMADE]

Yup,,,,,you think shorts are trying to force profits???? LOL

[TheFinalCD]

NRX 11'S SHEESH WAS HI AS $18 LAST TRADING DAY

[MONEYMADE]

,,,,,,,Ready for another interesting/exciting heart-pounding day?!?!?! HAHAAA!


--MONEYMADE
TALENT ON LOAN FROM GOD!!!

[bullrider2]

Yes, what a day for NephroGenex, from $4 plus closing yesterday, to $17.98 highs for today. Down after hours to $12.75. Neuroderm did the same thing yesterday from $6.18 to $19.97, down to $13.90 today after hours. NRX could be a $20 stock if we get a another excellent PR by the beginning of next week.

HAPPY PROSPEROUS NEW YEAR TO ALL.

[bullrider2]

It ran to $17.98 today.

[trunkmonk]

WOW what a day for NRX.

[TheFinalCD]

http://seekingalpha.com/news/1924175-more-on-nephrogenex-q2-results

[TheFinalCD]

WEIRD= LATE REACTION TO TUES A/H NEWS @ 4:05PM= http://finance.yahoo.com/news/nephrogenex-announces-positive-results-qt-210500634.html


IMAGINE SEEING NEWS YESTERDAY AND SELLING BECAUSE IT DIDNT DO WELL

[TheFinalCD]

23M VOLUME WITH 8M FLOAT= WTFREAK!!!!= http://finviz.com/quote.ashx?t=NRX&ty=c&ta=1&p=d

[ClayTrader]

* * $NRX Video Chart 12-31-14 * *

Link to Video - click here to watch the technical chart video

[TheFinalCD]

THOSE ANNOYING OUT OF ORDER $11 PRINTS

[TheFinalCD]

LOL

[oxnous]

Could not have happened to a better bunch of jerks. I do not mind HONEST negativity. But when they pile on and try to manipulate a stock down, that is where I draw the line.

More wine!